-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 28, Hengrui Pharmaceutical Class 3 generic drug Grombromide injection was officially approved by the State Drug Administration listed, becoming the first Glon ammonium bromide injection approved manufacturers.
Grome ammonium bromide injection is an anticholinel energy drug, mainly for pre-anesthesia and intraoperative drugs, used to fight muscle pine antagonists, such as Nismin drugs, such as intestinal peristaltic enhancement, increased secretions, bronchial spasms and slow heart rate and other toxic side effects.
Domestic preoperative use of anticholine drugs have atopyb, tobaalkali and pyridoline hydrochloride, atopyte as a clinical classic drug has been widely used so far, clinical applications, but the commonly used dose of atopenin can cause heart rate to increase faster, and the inhibitory effect of east palatealkali on respiratory gland secretion is slightly weaker than atopine, and atopin, east palladiumand saline ether can pass through the blood barrier.
Compared with Athosin, ammonium Glon bromide inhibits salivary secretion for a strong and long-lasting effect, with low cardiovascular adverse reactions, and the drug lipid membrane has poor passability and is not easy to pass through the blood-brain barrier, thus affecting the central nervous system less.
bromide is an ideal alternative to ato.
ammonium bromide injection makes up for the shortage of existing clinical therapies and can better meet clinical needs.
2017 global sales of about $180 million (source: IQVIA database), only Grombromin tablets (Tontine Pharmaceuticals) have been approved for market in China.
first submitted an application for the listing of Glon ammonium bromide injections in May 2018 and was included in the priority review in September of the same year as an "innovative drug with significant therapeutic advantages".
china also has Yuandong Bio, Jiabo Pharmaceuticals and Coastal Pharmaceuticals submitted applications for the drug to market.
.